Claims

What is claimed is:

1. A composition comprising latanoprost, isopropyl myristate, and petroleum jelly.

2. The composition of claim 1, consisting essentially of latanoprost, isopropyl myristate, and petroleum jelly.

3. The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w.

4. The composition of claim 3, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w.

5. The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w.

6. The composition of claim 5, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w.

7. The composition of claim 1, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w.

8. The composition of claim 7 wherein the isopropyl myristate concentration is between about 1% and about 10% w/w.

9. The composition of claim 7 wherein the isopropyl myristate concentration is between about 5% and about 15% w/w.

10. The composition of claim 2, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w.

11. The composition of claim 10, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w.

12. The composition of claim 10, wherein the isopropyl myristate concentration is between about 5% and about 15% w/w.

13. The composition of claim 1, wherein the petroleum jelly concentration is between about 70% and about 99% w/w.

14. The composition of claim 2, wherein the petroleum jelly concentration is between about 70% and about 99% w/w.

15. The composition of claim 1, further comprising a preservative.

16. The composition of claim 2, further comprising a preservative.

17. The composition of claim 1, wherein the composition is sterile.

18. The composition of claim 2, wherein the composition is sterile.

19. The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w.

20. The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w.

Claims

What is claimed is:

1. A composition comprising latanoprost and isopropyl myristate.

2. The composition of claim 1, wherein latanoprost concentration is between about 0.05 percent and about 0.5 percent of the final composition, by weight of the total weight of the composition.

3. A composition comprising tafluprost and isopropyl myristate.

4. The composition of claim 3, wherein tafluprost concentration is between about 0.01 percent and about 0.1 percent of the final composition, by weight of the total weight of the composition.

5. The composition of any one of claims 1-4, wherein the composition comprises between about 1 percent and about 20 percent of isopropyl myristate, by weight of the total weight of the composition.

6. The composition of claim 5 wherein the composition comprises between about 1 percent and about 10 percent isopropyl myristate, by weight of the total weight of the composition.

7. The composition of claim 5, further comprising an ointment base.

8. The composition of claim 7, wherein the ointment base is petroleum jelly.

9. The composition of claim 8, wherein the composition comprises between about 70 percent and about 99 percent petroleum jelly, by weight of the total weight of the composition.

10. The composition of claim 5, further comprising propylene glycol.

11. The composition of claim 10, wherein the composition comprises between about 5 percent and about 20 percent propylene glycol, by weight of the total weight of the composition.

12. The composition of claim 5, wherein the composition is sterile.

13. A method for reducing fat in a subject suffering from steatoblepharon, comprising applying to an eyelid of the subject a composition of claim 12.

14. A method for reducing body fat in a subject in need thereof, comprising topically administering a composition of claim 5 to the subject.

15. A composition of any one of claims 1-12 for use in a method for reducing body fat in a subject.

16. A composition of any one of claims 1-12 for use in for reducing fat in a subject suffering from steatoblepharon.

17. Use of a composition of any one of claims 1-12 in the manufacture of a medicament for reducing body fat in a subject.

18. A process for manufacturing a sterile ointment, comprising:
dissolving latanoprost in isopropyl myristate to make a solution;
microfiltration of the solution to make a filtrate; and
combining the filtrate with petroleum jelly.

19. A process for manufacturing a sterile ointment, comprising:
dissolving tafluprost in isopropyl myristate to make a solution;
microfiltration of the solution to make a filtrate; and
combining the filtrate with petroleum jelly.